For in vitro diagnostic use. Others Elecsys free PSA IVD Elecsys® free PSA CPS_000471 08828610214 free PSA Elecsys E2G 300 V2 Elecsys free PSA 07613336199954 Reagents, kits 300 tests cobas e 402/801 true 03289788160 free PSA Elecsys cobas e 100 V2 Elecsys free PSA 07613336154397 Reagents, kits 100 tests cobas e 411/601/602 true 08828601160 free PSA Elecsys cobas e 100 V3 Elecsys free PSA 07613336166673 Reagents, kits 100 tests cobas e 411/601/602 true 03289788190 free PSA Elecsys cobas e 100 V2 Elecsys free PSA 04015630936953 Reagents, kits 100 tests cobas e 411/601/602 true 08828601190 free PSA Elecsys cobas e 100 V3 Elecsys free PSA 07613336166611 Reagents, kits 100 tests cobas e 411/601/602 true 09744908190 free PSA Elecsys E2G 100 V2 free PSA Elecsys E2G 100 V2 07613336217672 Reagents, kits 100 tests cobas e 402/801 true 08828610190 free PSA Elecsys E2G 300 V2 Elecsys free PSA 07613336166628 Reagents, kits 300 tests cobas e 402/801 true 07027320190 free PSA Elecsys E2G 300 Elecsys free PSA 04015630940011 Reagents, kits 300 tests cobas e 402/801 true 08828610500 Elecsys free PSA en 6 FF00000005A1820E FF00000005A1820E 08828610190 08828610214 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of free prostate‑specific antigen in human serum and plasma.This assay is indicated for measurement of fPSA in conjunction with the Elecsys total PSA assay to develop a ratio (% fPSA) of fPSA to tPSA. This ratio is useful when used in conjunction with the Elecsys total PSA test as an aid in distinguishing prostate cancer from benign prostatic conditions in men age 50 years or older who have a digital rectal examination (DRE) that is not suspicious for prostate cancer and an Elecsys total PSA value in the range 4 ng/mL to 10 ng/mL. Prostate biopsy is required for the diagnosis of prostate cancer.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en ms_03289788160_USA Elecsys free PSA en 12 FF0000000385960E FF000000004DE20E 03289788160 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of free prostate‑specific antigen in human serum and plasma.This immunoassay is indicated for measurement of fPSA in conjunction with the Elecsys total PSA assay to develop a ratio (% fPSA) of fPSA to tPSA. This ratio is useful when used in conjunction with the Elecsys total PSA test as an aid in distinguishing prostate cancer from benign prostatic conditions in men age 50 years or older who have a digital rectal examination (DRE) that is not suspicious for prostate cancer and an Elecsys total PSA value in the range 4.00 ng/mL to 10.0 ng/mL. Prostate biopsy is required for the diagnosis of prostate cancer.The electrochemiluminescence immunoassay “ECLIA” is intended for use on Elecsys and cobas e immunoassay analyzers. en ms_03289788160_USA Elecsys free PSA en 11 FF00000003395D0E FF0000000305630E 03289788160 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of free prostate‑specific antigen in human serum and plasma.This immunoassay is indicated for measurement of fPSA in conjunction with the Elecsys total PSA assay to develop a ratio (% fPSA) of fPSA to tPSA. This ratio is useful when used in conjunction with the Elecsys total PSA test as an aid in distinguishing prostate cancer from benign prostatic conditions in men age 50 years or older who have a digital rectal examination (DRE) that is not suspicious for prostate cancer and an Elecsys total PSA value in the range 4.00 ng/mL to 10.0 ng/mL. Prostate biopsy is required for the diagnosis of prostate cancer.The electrochemiluminescence immunoassay “ECLIA” is intended for use on Elecsys and cobas e immunoassay analyzers. en 08828601501 Elecsys free PSA en 2 FF0000000698AA0E FF0000000455DB0E 08828601160 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of free prostate‑specific antigen in human serum and plasma.This immunoassay is indicated for measurement of fPSA in conjunction with the Elecsys total PSA assay to develop a ratio (% fPSA) of fPSA to tPSA. This ratio is useful when used in conjunction with the Elecsys total PSA test as an aid in distinguishing prostate cancer from benign prostatic conditions in men age 50 years or older who have a digital rectal examination (DRE) that is not suspicious for prostate cancer and an Elecsys total PSA value in the range 4.00 ng/mL to 10.0 ng/mL. Prostate biopsy is required for the diagnosis of prostate cancer.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en ms_03289788190 Elecsys free PSA en 14 FF00000003608F0E FF0000000030A10E 03289788190 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of free prostate‑specific antigen in human serum and plasma.This assay is indicated for measurement of fPSA in conjunction with the Elecsys total PSA assay to develop a ratio (% fPSA) of fPSA to tPSA. This ratio is useful when used in conjunction with the Elecsys total PSA test as an aid in distinguishing prostate cancer from benign prostatic conditions in men age 50 years or older who have a digital rectal examination (DRE) that is not suspicious for prostate cancer and an Elecsys total PSA value in the range 4 ng/mL to 10 ng/mL. Prostate biopsy is required for the diagnosis of prostate cancer.The electrochemiluminescence immunoassay “ECLIA” is intended for use on Elecsys and cobas e immunoassay analyzers. en 08828601500 Elecsys free PSA en 4 FF00000004646E0E FF0000000392320E 08828601190 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of free prostate‑specific antigen in human serum and plasma.This assay is indicated for measurement of fPSA in conjunction with the Elecsys total PSA assay to develop a ratio (% fPSA) of fPSA to tPSA. This ratio is useful when used in conjunction with the Elecsys total PSA test as an aid in distinguishing prostate cancer from benign prostatic conditions in men age 50 years or older who have a digital rectal examination (DRE) that is not suspicious for prostate cancer and an Elecsys total PSA value in the range 4 ng/mL to 10 ng/mL. Prostate biopsy is required for the diagnosis of prostate cancer.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 08828610501 Elecsys free PSA en 2 FF00000006245F0E FF00000006245F0E 08828610190 09744908190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of free prostate‑specific antigen in human serum and plasma.This immunoassay is indicated for measurement of fPSA in conjunction with the Elecsys total PSA assay to develop a ratio (% fPSA) of fPSA to tPSA. This ratio is useful when used in conjunction with the Elecsys total PSA test as an aid in distinguishing prostate cancer from benign prostatic conditions in men age 50 years or older who have a digital rectal examination (DRE) that is not suspicious for prostate cancer and an Elecsys total PSA value in the range 4.00 ng/mL to 10.0 ng/mL. Prostate biopsy is required for the diagnosis of prostate cancer.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 09744908501 Elecsys free PSA en 1 FF0000000730FE0E FF00000006245B0E 09744908190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of free prostate‑specific antigen in human serum and plasma.This immunoassay is indicated for measurement of fPSA in conjunction with the Elecsys total PSA assay to develop a ratio (% fPSA) of fPSA to tPSA. This ratio is useful when used in conjunction with the Elecsys total PSA test as an aid in distinguishing prostate cancer from benign prostatic conditions in men age 50 years or older who have a digital rectal examination (DRE) that is not suspicious for prostate cancer and an Elecsys total PSA value in the range 4.00 ng/mL to 10.0 ng/mL. Prostate biopsy is required for the diagnosis of prostate cancer.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 09744908500 Elecsys free PSA en 1 FF00000007257D0E FF00000007257D0E 09744908190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of free prostate‑specific antigen in human serum and plasma.This assay is indicated for measurement of fPSA in conjunction with the Elecsys total PSA assay to develop a ratio (% fPSA) of fPSA to tPSA. This ratio is useful when used in conjunction with the Elecsys total PSA test as an aid in distinguishing prostate cancer from benign prostatic conditions in men age 50 years or older who have a digital rectal examination (DRE) that is not suspicious for prostate cancer and an Elecsys total PSA value in the range 4 ng/mL to 10 ng/mL. Prostate biopsy is required for the diagnosis of prostate cancer.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 08828610501 Elecsys free PSA en 1 FF00000004582F0E FF00000004582F0E 08828610190 2497 cobas e 801 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of free prostate‑specific antigen in human serum and plasma.This immunoassay is indicated for measurement of fPSA in conjunction with the Elecsys total PSA assay to develop a ratio (% fPSA) of fPSA to tPSA. This ratio is useful when used in conjunction with the Elecsys total PSA test as an aid in distinguishing prostate cancer from benign prostatic conditions in men age 50 years or older who have a digital rectal examination (DRE) that is not suspicious for prostate cancer and an Elecsys total PSA value in the range 4.00 ng/mL to 10.0 ng/mL. Prostate biopsy is required for the diagnosis of prostate cancer.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 08828610500 Elecsys free PSA en 2 FF00000003D9690E FF0000000364240E 08828610190 2497 cobas e 801 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of free prostate‑specific antigen in human serum and plasma.This assay is indicated for measurement of fPSA in conjunction with the Elecsys total PSA assay to develop a ratio (% fPSA) of fPSA to tPSA. This ratio is useful when used in conjunction with the Elecsys total PSA test as an aid in distinguishing prostate cancer from benign prostatic conditions in men age 50 years or older who have a digital rectal examination (DRE) that is not suspicious for prostate cancer and an Elecsys total PSA value in the range 4 ng/mL to 10 ng/mL. Prostate biopsy is required for the diagnosis of prostate cancer.The electrochemiluminescence immunoassay “ECLIA” is intended for use on the cobas e 801 immunoassay analyzer. en 08828610500 Elecsys free PSA en 5 FF000000053E9B0E FF0000000452FB0E 08828610190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of free prostate‑specific antigen in human serum and plasma.This assay is indicated for measurement of fPSA in conjunction with the Elecsys total PSA assay to develop a ratio (% fPSA) of fPSA to tPSA. This ratio is useful when used in conjunction with the Elecsys total PSA test as an aid in distinguishing prostate cancer from benign prostatic conditions in men age 50 years or older who have a digital rectal examination (DRE) that is not suspicious for prostate cancer and an Elecsys total PSA value in the range 4 ng/mL to 10 ng/mL. Prostate biopsy is required for the diagnosis of prostate cancer.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 08828610500 Elecsys free PSA en 1 FF0000000364240E FF0000000364230E 08828610190 2497 cobas e 801 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of free prostate‑specific antigen in human serum and plasma.This assay is indicated for measurement of fPSA in conjunction with the Elecsys total PSA assay to develop a ratio (% fPSA) of fPSA to tPSA. This ratio is useful when used in conjunction with the Elecsys total PSA test as an aid in distinguishing prostate cancer from benign prostatic conditions in men age 50 years or older who have a digital rectal examination (DRE) that is not suspicious for prostate cancer and an Elecsys total PSA value in the range 4 ng/mL to 10 ng/mL. Prostate biopsy is required for the diagnosis of prostate cancer.The electrochemiluminescence immunoassay “ECLIA” is intended for use on the cobas e 801 immunoassay analyzer. en 07027320501 Elecsys free PSA en 3 FF0000000337FE0E FF0000000317890E 07027320190 2497 cobas e 801 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of free prostate‑specific antigen in human serum and plasma.This immunoassay is indicated for measurement of fPSA in conjunction with the Elecsys total PSA assay to develop a ratio (% fPSA) of fPSA to tPSA. This ratio is useful when used in conjunction with the Elecsys total PSA test as an aid in distinguishing prostate cancer from benign prostatic conditions in men age 50 years or older who have a digital rectal examination (DRE) that is not suspicious for prostate cancer and an Elecsys total PSA value in the range 4.00 ng/mL to 10.0 ng/mL. Prostate biopsy is required for the diagnosis of prostate cancer.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 07027320500 Elecsys free PSA en 3 FF000000021B710E FF0000000189740E 07027320190 2497 cobas e 801 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of free prostate‑specific antigen in human serum and plasma.This assay is indicated for measurement of fPSA in conjunction with the Elecsys total PSA assay to develop a ratio (% fPSA) of fPSA to tPSA. This ratio is useful when used in conjunction with the Elecsys total PSA test as an aid in distinguishing prostate cancer from benign prostatic conditions in men age 50 years or older who have a digital rectal examination (DRE) that is not suspicious for prostate cancer and an Elecsys total PSA value in the range 4 ng/mL to 10 ng/mL. Prostate biopsy is required for the diagnosis of prostate cancer.The electrochemiluminescence immunoassay “ECLIA” is intended for use on the cobas e 801 immunoassay analyzer. en